Journal article

International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013).

Vito Amoroso, Daniele Generali, Thomas Buchholz, Massimo Cristofanilli, Rebecca Pedersini, Giuseppe Curigliano, Maria Grazia Daidone, Serena Di Cosimo, Mitchell Dowsett, Stephen Fox, Adrian L Harris, Andreas Makris, Lucia Vassalli, Andrea Ravelli, Maria Rosa Cappelletti, Christos Hatzis, Clifford A Hudis, Paolo Pedrazzoli, Anna Sapino, Vladimir Semiglazov Show all

J Natl Cancer Inst Monogr | Published : 2015


Expert consensus-based recommendations regarding key issues in the use of primary (or neoadjuvant) systemic treatment (PST) in patients with early breast cancer are a valuable resource for practising oncologists. PST remains a valuable therapeutic approach for the assessment of biological antitumor activity and clinical efficacy of new treatments in clinical trials. Neoadjuvant trials provide endpoints, such as pathological complete response (pCR) to treatment, that potentially translate into meaningful improvements in overall survival and disease-free survival. Neoadjuvant trials need fewer patients and are less expensive than adjuvant trial, and the endpoint of pCR is achieved in months, r..

View full abstract